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Sir, 
We were pleased that Arrigo and colleagues (Arrigo et al. 2017b) were impressed by our 
recent review (Weil et al. 2016) and that they found it an accurate description of clinical and 
functional features found in Parkinson’s disease. Their recent work (Arrigo et al. 2017a) is a 
valuable contribution to the field. Their multi-modal approach that incorporates quantitative 
measures of white matter tracts provides important orthogonal information about the 
degenerative processes taking place early on in Parkinson’s disease. Of interest, they found 
changes in the microstructure of white matter tracts that occur early on in the visual 
processing pathway, including in the optic radiation. Other groups have also made important 
contributions in this area (Pereira et al. 2014;Shine et al. 2015). 
We agree that to better understand the pathological processes underlying Parkinson’s disease 
it will be important to use techniques that go beyond grey matter volume measurements that 
are sensitive to neuronal death (Rossor et al. 1997). Effects of pathological accumulations 
within axons may be a more critical early feature of Parkinson’s disease (Chung et al. 
2009;Orimo et al. 2008) and these can be detected using quantitative measures of white 
matter microstructure. Where white matter and grey matter are measured concurrently in 
Parkinson’s disease, changes in white matter microstructure precede grey matter loss 
(Duncan et al. 2016;Hattori et al. 2012). Focal mean diffusivity correlates with domain-
specific loss of cognitive function in Parkinson’s disease and occurs prior to reduction in 
fractional anisotropy or grey matter volume (Melzer et al. 2013). 
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Similarly, new technologies are emerging that are sensitive to alterations in brain tissue 
composition. These have the potential to provide important insights into the biological 
mechanisms of Parkinson’s disease. For example, quantitative susceptibility mapping, which 
is sensitive to iron content, can detect abnormalities in brainstem and cortex in Parkinson’s 
disease, that cannot be detected using conventional grey and white matter imaging (Acosta-
Cabronero et al. 2017). Furthermore advances in diffusion imaging, such as neurite 
orientation dispersion and density (Zhang et al. 2012) and multi-shell global tractography 
(Christiaens et al. 2015) now allow detailed characterisation of white matter microstructure 
and white matter brain networks, respectively.   
In parallel with these advances in image analysis is the mounting evidence that topological 
features of healthy brain networks can predict both grey and white matter loss in a range of 
neurodegenerative diseases (Seeley et al. 2009;Zhou et al. 2012;Mandelli et al. 2016). This 
represents a step change from the detection of group differences between patients and healthy 
populations to systems level mechanisms that can account for the selective vulnerability of 
specific brain regions in neurodegenerative disease. In this respect, connectomics and graph 
theoretical analysis approaches are providing important new insights into organisational 
principles that can account for selective vulnerability in Parkinson’s disease. For example, 
Zeighami and colleagues (Zeighami et al. 2015) showed that intrinsic functional networks of 
the healthy brain and network proximity to the substantia nigra, the proposed disease 
epicentre in Parkinson’s, could account for grey matter atrophy patterns in Parkinson’s 
disease relative to controls. This provides evidence to support the model of cell-to-cell 
propagation of alpha synuclein in Parkinson’s disease. These techniques are also proving to 
be particularly sensitive to early variations, with changes in connectivity patterns seen before 
differences can be detected using conventional measures (Pereira et al. 2015). Critically, 
some of the earliest network changes, seen even in drug naïve Parkinson’s patients, are found 
in temporo-occipital regions and correlate with performance in visuo-perceptual measures 
(Luo et al. 2015). 
These multi-modal approaches will be important in gaining a better understanding of the 
pathological processes that underlie Parkinson’s disease and in determining the earliest 
neuroimaging signature of disease, in order to identify patients that may in future benefit 
from disease modifying treatments.  
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